Development of the atherosclerotic plaque

Cardiovascular Plaque Rupture

Volumn , Issue , 2002, Pages 1-50

  Berman, Joan W ^a   Kazimi, Marwan ^a   Ma, Harry ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869481746     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (280)

1. Cohen JD, Grimm RH Jr, Smith WM. Multiple risk factor intervention trial (MRFIT). Prev Med 1981; 10: 501-518.
2. Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary heart disease. Circulation 1966; 34: 553-555.
3. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976; 38: 46-51.
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
5. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 9: I19-32.
6. Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680-2690.
7. Ross R. Mechanisms of atherosclerosis-a review. Adv Nephrol Necker Hosp 1990; 19: 79-86.
8. Fuster V. Human lesion studies. Ann N Y Acad Sci 1997; 811: 207-224; discussion 224-225.
9. Gonzalez ER, Kannewurf BS. Atherosclerosis: a unifying disorder with diverse manifestations. Am J Health Syst Pharm 1998; 55: S4-7.
10. Kannel WB. Overview of atherosclerosis. Clin Ther 1998; 20: B2-17.
11. 1999 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 1998.
12. Stone NJ. The clinical and economic significance of atherosclerosis. Am J Med 1996; 101: 4A6S-9S.
13. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355-1374.
14. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology [published erratum appears in Circulation 1995 Jan 1;91(1): 256]. Circulation 1994; 90: 2126-2146.
15. Denke MA. Diet and lifestyle modification and its relationship to atherosclerosis. Med Clin North Am 1994; 78: 197-223.
16. Nehler MR, Taylor LM Jr, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg 1997; 5: 559-567.
17. Kannel WB. New perspectives on cardiovascular risk factors. Am Heart J 1987; 114: 213-219.
18. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-2148.
19. Ellis RW. Infection and coronary heart disease. J Med Microbiol 1997; 46: 535-539.
20. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 1993; 14(suppl K): 12-16.
21. Experimental atherosclerosis in rabbits. Nutr Rev 1965; 23: 329-330.
22. Reddick RL, Read MS, Brinkhous KM, Bellinger D, Nichols T, Griggs TR. Coronary atherosclerosis in the pig. Induced plaque injury and platelet response. Arteriosclerosis 1990; 10: 541-550.
23. Mahley RW, Weisgraber KH, Innerarity T. Atherogenic hyperlipoproteinemia induced by cholesterol feeding the Patas monkey. Biochemistry 1976; 15: 2979-2985.
24. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
25. Hopp L, Gilboa N, Kurland G, Weichler N, Orchard TJ. Acute myocardial infarction in a young boy with nephrotic syndrome: a case report and review of the literature. Pediatr Nephrol 1994; 8: 290-294.
26. Stehbens WE. The epidemiological relationship of hypercholesterolemia, hypertension, diabetes mellitus and obesity to coronary heart disease and atherogenesis. J Clin Epidemiol 1990; 43: 733-741.
27. Cullen P, Funke H, Schulte H, Assmann G. Lipoproteins and cardiovascular riskfrom genetics to CHD prevention. J Atheroscler Thromb 1997; 4: 51-58.
28. Wissler RW. Evidence for regression of advanced atherosclerotic plaques. Artery 1979; 5: 398-408.
29. Nash DT, Gensini G, Esente P. Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol 1982; 2: 43-55.
30. Olsson AG, Carlson LA, Erikson U, Hemius G, Hemmingsson A, Ruhn G. Regression of computer estimated femoral atherosclerosis after pronounced serum lipid lowering in patients with asymptomatic hyperlipidaemia [letter]. Lancet 1982; 1: 1311.
31. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971; 74: 1-12.
32. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
33. Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. Arch Pathol Lab Med 1988; 112: 1032-1040.
34. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest 1990; 85: 144-151.
35. Blankenhorn DH, Johnson RL, Mack WJ, el Zein HA, Vailas LI. The influence of diet on the appearance of new lesions in human coronary arteries [see comments]. Jama 1990; 263: 1646-1652.
36. Knapp HR, Reilly IA, Alessandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986;314: 937-942.
37. Hennig B, Chow CK. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Radic Biol Med 1988; 4: 99-106.
38. Chobanian AV. The influence of hypertension and other hemodynamic factors in atherogenesis. Prog Cardiovasc Dis 1983; 26: 177-196.
39. McGill HC, Jr. The cardiovascular pathology of smoking. Am Heart J 1988; 115: 250-257.
40. Benowitz NL. The role of nicotine in smoking-related cardiovascular disease. Prev Med 1997; 26: 412-417.
41. Pyorala K. Diabetes and coronary heart disease. Acta Endocrinol Suppl 1985; 272: 11-19.
42. Stout RW. Diabetes and atherosclerosis. Biomed Pharmacother 1993; 47: 1-2.
43. Howard G, O’Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators [see comments]. Circulation 1996; 93: 1809-1817.
44. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
45. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979; 32: 563-576.
46. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980; 302: 1383-1389.
47. Elliott TG, Viberti G. Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. Baillieres Clin Endocrinol Metab 1993; 7: 1079-1103.
48. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141.
49. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160.
50. Howard G, Bergman R, Wagenknecht LE, et al. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the “minimal model.'' Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998; 8: 358-369.
51. Wagenknecht LE, Mayer EJ, Rewers M, et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 1995; 5: 464-472.
52. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-162.
53. Ferrara A, Barrett-Connor E, Wingard DL, Edelstein SL. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance statu. The Rancho Bernardo Study, 1984-1987. Diabetes Care 1995; 18: 220-225.
54. Reaven P, Merat S, Casanada F, Sutphin M, Palinski W. Effect of streptozotocininduced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 1997; 17: 2250-2256.
55. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998; 105: 4S-14S.
56. King GL, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996; 25: 255-270.
57. Richardson M, Hadcock SJ, DeReske M, Cybulsky MI. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 1994; 14: 760-769.
58. Nishio Y, Kashiwagi A, Taki H, et al. Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 1998; 47: 1318-1325.
59. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497.
60. Miller TD, Balady GJ, Fletcher GF. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med 1997; 19: 220-229.
61. Manolio TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993; 88: 2163-2171.
62. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial [see comments] [published erratum appears in JAMA 1995 Dec 6;274(21): 1676].
63. JAMA 1995; 273: 199-208.
64. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
65. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism 1992; 41: 1110-1114.
66. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136: 23-28.
67. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993; 14(suppl K): 30-38.
68. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150: 1785-1790.
69. Nicholson AC, Hajjar DP. Herpesvirus in atherosclerosis and thrombosis: etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vasc Biol 1998; 18: 339-348.
70. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
71. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
72. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 1995; 41: 173-176.
73. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev 1995; 53: 283-288.
74. Omenn GS, Beresford SA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine [editorial; comment]. Circulation 1998; 97: 421-424.
75. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
76. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081.
77. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
78. McGill HC Jr. George Lyman Duff memorial lecture. Persistent problems in the pathogenesis of atherosclerosis. Arteriosclerosis 1984; 4: 443-451.
79. Wissler RW, Strong JP. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol 1998; 153: 1023-1033.
80. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-229.
81. Watanabe T, Haraoka S, Shimokama T. Inflammatory and immunological nature of atherosclerosis. Int J Cardiol 1996; 54(suppl): S51-60.
82. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138.
83. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86: 675-684.
84. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-20966.
85. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831-842.
86. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-1076.
87. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease [editorial; comment]. Circulation 1997; 96: 3264-3265.
88. Kim JA, Gu JL, Natarajan R, Berliner JA, Nadler JL. A leukocyte type of 12- lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 1995; 15: 942-948.
89. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res 1995; 18: 87-98.
90. Serrano CV Jr, Mikhail EA, Wang P, Noble B, Kuppusamy P, Zweier JL. Superoxide and hydrogen peroxide induce CD18-mediated adhesion in the postischemic heart. Biochim Biophys Acta 1996; 1316: 191-202.
91. Lyons D. Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int J Cardiol 1997; 62(Suppl 2): S101-109.
92. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shearstress- responsive element [published erratum appears in Proc Natl Acad Sci USA 1993 Aug 15;90(16): 7908]. Proc Natl Acad Sci USA 1993; 90: 4591-4595.
93. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest 1994; 94: 885-891.
94. Steinberg D. Lipoproteins and the pathogenesis of atherosclerosis. Circulation 1987; 76: 508-514.
95. Knight BL, Soutar AK. Degradation of normal and abnormal plasma lipoproteins by cultured macrophages. Agents Actions Suppl 1984; 16: 129-143.
96. Ottnad E, Parthasarathy S, Sambrano GR, et al. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells. Proc Natl Acad Sci USA 1995; 92: 1391-1395.
97. Sambrano GR, Steinberg D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc Natl Acad Sci USA 1995; 92: 1396-1400.
98. Clinton SK, Underwood R, Hayes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol 1992; 140: 301-316.
99. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981; 78: 6499-6503.
100. Steinbrecher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-3608.
101. Parthasarathy S, Quinn MT, Steinberg D. Is oxidized low density lipoprotein involved in the recruitment and retention of monocyte/macrophages in the artery wall during the initiation of atherosclerosis? Basic Life Sci 1988; 49: 375-380.
102. Mougenot N, Lesnik P, Ramirez-Gil JF, et al. Effect of the oxidation state of LDL on the modulation of arterial vasomotor response in vitro. Atherosclerosis 1997; 133: 183-192.
103. Thorne SA, Abbot SE, Winyard PG, Blake DR, Mills PG. Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart 1996; 75: 11-16.
104. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
105. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85: 2805-2809.
106. Quinn MT, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA 1985; 82: 5949-5953.
107. Deigner HP, Claus R. Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett 1996; 385: 149-153.
108. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254-257.
109. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
110. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134-5138.
111. Rosenfeld ME, Khoo JC, Miller E, Parthasarathy S, Palinski W, Witztum JL. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J Clin Invest 1991; 87: 90-99.
112. Zhang HF, Basra HJ, Steinbrecher UP. Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J Lipid Res 1990; 31: 1361-1369.
113. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376.
114. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 1998; 9: 441-448.
115. Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 1994; 14: 438-442.
116. Pritchard KA Jr, Total RR, Lin JH, et al. Native low density lipoprotein. Endothelial cell recruitment of mononuclear cells. Arterioscler Thromb 1991; 11: 1175-1181.
117. Smalley DM, Lin JH, Curtis ML, Kobari Y, Stemerman MB, Pritchard KA Jr. Native LDL increases endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol 1996; 16: 585-590.
118. Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein- induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest 1998; 101: 1064-1075.
119. Lin JH, Zhu Y, Liao HL, Kobari Y, Groszek L, Stemerman MB. Induction of vascular cell adhesion molecule-1 by low-density lipoprotein. Atherosclerosis 1996; 127: 185-194.
120. Ko Y, Totzke G, Seewald S, et al. Native low-density lipoprotein (LDL) induces the expression of the early growth response gene-1 in human umbilical arterial endothelial cells. Eur J Cell Biol 1995; 68: 306-312.
121. Cominacini L, Garbin U, Fratta Pasini A, et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997; 15: 1633-1640.
122. Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1997; 1345: 93-98.
123. Zhu Y, Lin JH, Liao HL, et al. LDL induces transcription factor activator protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 473-480.
124. Yamakawa T, Eguchi S, Yamakawa Y, et al. Lysophosphatidylcholine stimulates MAP kinase activity in rat vascular smooth muscle cells. Hypertension 1998; 31: 248-253.
125. Chatterjee S, Bhunia AK, Snowden A, Han H. Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p44 mitogen activated protein kinase and c- fos expression in aortic smooth muscle cells. Glycobiology 1997; 7: 703-710.
126. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma. Cell 1998; 93: 229-240.
127. Das PK, de Boer OJ, Visser A, Verhagen CE, Bos JD, Pals ST. Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis. Acta Derm Venereol Suppl 1994; 186: 21-22.
128. Ferro CJ, Webb DJ. Endothelial dysfunction and hypertension. Drugs 1997; 53: 30-41.
129. Cotran RS, Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol Biol (Paris) 1998; 46: 164-170.
130. Tenaglia AN, Buda AJ, Wilkins RG, et al. Levels of expression of P-selectin, Eselectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 1997; 79: 742-747.
131. Frenette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost 1997; 78: 60-64.
132. Austrup F, Vestweber D, Borges E, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997; 385: 81-83.
133. Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997; 99: 1037-1043.
134. Vora DK, Fang ZT, Liva SM, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997; 80: 810-818.
135. Johnson-Tidey RR, McGregor JL, Taylor PR, Poston RN. Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol 1994; 144: 952-961.
136. Gonzalez-Amaro R, Diaz-Gonzalez F, Sanchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs 1998; 56: 977-988.
137. Nageh MF, Sandberg ET, Marotti KR, et al. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1997; 17: 1517-1520.
138. Ruffolo RR, Jr., Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 1997; 11(Suppl 1): 247-256.
139. Cotran RS, Gimbrone MA Jr, Bevilacqua MP, Mendrick DL, Pober JS. Induction and detection of a human endothelial activation antigen in vivo. J Exp Med 1986; 164: 661-666.
140. Tanaka Y, Albelda SM, Horgan KJ, et al. CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. J Exp Med 1992; 176: 245-253.
141. Calderon TM, Factor SM, Hatcher VB, Berliner JA, Berman JW. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9. Expression in vivo in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels. Lab Invest 1994; 70: 836-849.
142. McEvoy LM, Sun H, Tsao PS, Cooke JP, Berliner JA, Butcher EC. Novel vascular molecule involved in monocyte adhesion to aortic endothelium in models of atherogenesis. J Exp Med 1997; 185: 2069-2077.
143. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10(Suppl 1): S9-12.
144. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factorkappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
145. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999; 19: 1-47.
146. Wang JM, Su S, Gong W, Oppenheim JJ. Chemokines, receptors, and their role in cardiovascular pathology. Int J Clin Lab Res 1998; 28: 83-90.
147. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997; 349: 490-495.
148. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998; 9: 397-405.
149. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-5256.
150. Wempe F, Lindner V, Augustin HG. Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 2471-2478.
151. Lei XF, Ohkawara Y, Stampfli MR, et al. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin Invest 1998; 101: 1342-1353.
152. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997; 151: 1085-1095.
153. Kitamura M. Identification of an inhibitor targeting macrophage production of monocyte chemoattractant protein-1 as TGF-beta 1. J Immunol 1997; 159: 1404-1411.
154. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 1996; 16: 673-677.
155. Torzewski M, Torzewski J, Bowyer DE, et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997; 17: 2448-2452.
156. Gyetko MR, Todd RF 3rd, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380-1387.
157. Faull RJ, Ginsberg MH. Inside-out signaling through integrins. J Am Soc Nephrol 1996; 7: 1091-1097.
158. Berkhout TA, Sarau HM, Moores K, et al. Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B. J Biol Chem 1997; 272: 16404-16413.
159. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994; 1: S10-13.
160. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996; 15: 1194-1199.
161. Fairchild RL, VanBuskirk AM, Kondo T, Wakely ME, Orosz CG. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation 1997; 63: 1807-1812.
162. Hoch RC, Schraufstatter IU, Cochrane CG. In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors. J Lab Clin Med 1996; 128: 134-145.
163. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis [see comments]. Science 1992; 258: 1798-1801.
164. Oin S, LaRosa G, Campbell JJ, et al. Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur J Immunol 1996; 26: 640-647.
165. Brand K, Eisele T, Kreusel U, et al. Dysregulation of monocytic nuclear factorkappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17: 1901-1909.
166. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353-363.
167. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE, Tall A. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996; 271: 8837-8842.
168. Schwartz D, Andalibi A, Chaverri-Almada L, et al. Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest 1994; 94: 1968-1973.
169. Lukacs NW, Strieter RM, Elner V, Evanoff HL, Burdick MD, Kunkel SL. Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 1995; 86: 2767-2773.
170. Urakaze M, Temaru R, Satou A, Yamazaki K, Hamazaki T, Kobayashi M. The IL-8 production in endothelial cells is stimulated by high glucose. Horm Metab Res 1996; 28: 400-401.
171. Walz A, Meloni F, Clark-Lewis I, von Tscharner V, Baggiolini M. [Ca2_]i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/MGSA. J Leukoc Biol 1991; 50: 279-286.
172. Kocher O, Gabbiani F, Gabbiani G, et al. Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies. Lab Invest 1991; 65: 459-470.
173. Kocher O, Skalli O, Bloom WS, Gabbiani G. Cytoskeleton of rat aortic smooth muscle cells. Normal conditions and experimental intimal thickening. Lab Invest 1984; 50: 645-652.
174. Gabbiani G, Rungger-Brandle E, de Chastonay C, Franke WW. Vimentin-containing smooth muscle cells in aortic intimal thickening after endothelial injury. Lab Invest 1982; 47: 265-269.
175. Owens GK, Loeb A, Gordon D, Thompson MM. Expression of smooth musclespecific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 1986; 102: 343-352.
176. Okamoto E, Suzuki T, Aikawa M, et al. Diversity of the synthetic-state smoothmuscle cells proliferating in mechanically and hemodynamically injured rabbit arteries. Lab Invest 1996; 74: 120-128.
177. Simons M, Leclerc G, Safian RD, Isner JM, Weir L, Baim DS. Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. N Engl J Med 1993; 328: 608-613.
178. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992; 86: III43-46.
179. Davies PF, Tripathi SC. Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res 1993; 72: 239-245.
180. Ross R. Growth factors in the pathogenesis of atherosclerosis. Acta Med Scand Suppl 1987; 715: 33-38.
181. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
182. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137(suppl): S101-109.
183. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064.
184. Casscells W. Smooth muscle cell growth factors. Prog Growth Factor Res 1991; 3: 177-206.
185. Consigny PM, Bilder GM. Expression and release of smooth muscle cell mitogens in the arterial wall after balloon angioplasty. J Vas Med Biol 1993; 4: 1-8.
186. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol 1990; 111: 2149-2158.
187. Bowen-Pope DF, Hart CE, Seifert RA. Sera and conditioned media contain different isoforms of platelet-derived growth factor (PDGF) which bind to different classes of PDGF receptor. J Biol Chem 1989; 264: 2502-2508.
188. Major TC, Keiser JA. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther 1997; 283: 402-410.
189. Ross R. Platelet-derived growth factor. Lancet 1989; 1: 1179-1182.
190. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 1989; 9: 269-278.
191. Bjornsson TD, Dryjski M, Tluczek J, et al. Acidic fibroblast growth factor promotes vascular repair. Proc Natl Acad Sci USA 1991; 88: 8651-8655.
192. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992; 89: 465-473.
193. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA 1993; 90: 1513-1517.
194. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990; 85: 2004-2008.
195. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88: 3739-3743.
196. Nabel EG, Yang ZY, Plautz G, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362: 844-846.
197. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.
198. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-2274.
199. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 1991; 49: L223-228.
200. Bilazarian SD, Currier JW, Kakuta T, Haudenschild CC, Faxon DP. Angiotensin II antagonism does not prevent restenosis after rabbit iliac angioplasty (abstr). Circulation 1992; 86: I187.
201. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70: 591-614.
202. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by alpha-thrombin in vascular smooth muscle cells. Circ Res 1992; 71: 1285-1293.
203. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994; 81: 1254-1269.
204. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. Circulation 1998; 98: 580-587.
205. Heras M, Chesebro JH, Webster MW, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-1484.
206. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989; 84: 640-646.
207. Chan P, Munro E, Patel M, et al. Cellular biology of human intimal hyperplastic stenosis. Eur J Vasc Surg 1993; 7: 129-135.
208. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118: 253-256.
209. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987; 61: 296-300.
210. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
211. Tarry WC, Makhoul RG. l-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb 1994; 14: 938-943.
212. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
213. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992; 70: 593-599.
214. Taubman MB, Rollins BJ, Poon M, et al. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 1992; 70: 314-325.
215. Tanaka H, Sukhova GK, Swanson SJ, et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation 1993; 88: 1788-1803.
216. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10134-10139.
217. Marmur JD, Taubman MB, Fuster V. Pathophysiology of restenosis: the role of platelets and thrombin. Journal of Vascular Medicine and Biology 1993; 4: 55-63.
218. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989; 86: 8412-8416.
219. Koyama N, Harada K, Yamamoto A, Morisaki N, Saito Y, Yoshida S. Purification and characterization of an autocrine migration factor for vascular smooth muscle cells (SMC), SMC-derived migration factor. J Biol Chem 1993; 268: 13301-13308.
220. Jones JI, Doerr ME, Clemmons DR. Cell migration: interactions among integrins, IGFs and IGFBPs. Prog Growth Factor Res 1995; 6: 319-327.
221. Slepian MJ, Massia SP, Dehdashti B, Fritz A, Whitesell L. Beta3-integrins rather than betal-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation 1998; 97: 1818-1827.
222. Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10: 203-208.
223. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71: 850-858.
224. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques [see comments]. Lancet 1989; 2: 941-944.
225. Lundberg B. Chemical composition and physical state of lipid deposits in atherosclerosis. Atherosclerosis 1985; 56: 93-110.
226. Gertz SD, Roberts WC. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques [editorial]. Am J Cardiol 1990; 66: 1368-1372.
227. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
228. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see comments]. Lancet 1994; 344: 1383-1389.
229. Gronholdt ML, Dalager-Pedersen S, Falk E. Coronary atherosclerosis: determinants of plaque rupture. Eur Heart J 1998; 19 Suppl C: C24-29.
230. Arroyo LH, Lee RT. The unstable atheromatous plaque. Can J Cardiol 1998; 14(Suppl B): 11B-13B.
231. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-1230.
232. Lee RT, Berditchevski F, Cheng GC, Hemler ME. Integrin-mediated collagen matrix reorganization by cultured human vascular smooth muscle cells. Circ Res 1995; 76: 209-214.
233. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-848.
234. Lee RT, Kamm RD. Vascular mechanics for the cardiologist. J Am Coll Cardiol 1994; 23: 1289-1295.
235. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 1996; 14: 17-29.
236. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22: 1228-1241.
237. Barger AC, Beeuwkes Rd. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol 1990; 66: 41G-43G.
238. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997; 17: 1859-1867.
239. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 1994; 15: 25-29.
240. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-583.
241. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996; 271: 12517-12524.
242. Matrisian LM.Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-125.
243. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
244. Fabunmi RP, Sukhova GK, Sugiyama S, Libby P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res 1998; 83: 270-278.
245. Willenbrock F, Murphy G. Structure-function relationships in the tissue inhibitors of metalloproteinases [published erratum appears in Am J Respir Crit Care Med 1995 Mar; 151(3 Pt 1): 926]. Am J Respir Crit Care Med 1994; 150: S165-170.
246. Nikkari ST, O’Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398.
247. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
248. Ye S, Humphries S, Henney A. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin Sci (Colch) 1998; 94: 103-110.
249. Lee E, Grodzinsky AJ, Libby P, Clinton SK, Lark MW, Lee RT. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol 1995; 15: 2284-2289.
250. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990; 86: 1496-1502.
251. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402-406.
252. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
253. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-778.
254. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization [see comments]. Circulation 1998; 97: 2433-2444.
255. Kockx MM, Herman AG. Apoptosis in atherogenesis: implications for plaque destabilization. Eur Heart J 1998; 19(Suppl G): G23-28.
256. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme [see comments]. Am J Pathol 1995; 147: 251-266.
257. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996; 16: 19-27.
258. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-2843.
259. Taubman MB, Fallon JT, Schecter AD, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-204.
260. Schecter AD, Rollins BJ, Zhang YJ, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997; 272: 28568-28573.
261. Marmur JD, Rossikhina M, Guha A, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-2259.
262. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226-1232.
263. O’Brien ER, Garvin MR, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883-894.
264. Barger AC, Beeuwkes Rd, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984; 310: 175-177.
265. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998; 135: 10-14.
266. Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries. Arterioscler Thromb Vasc Biol 1999; 19: 131-139.
267. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995; 26: 450-456.
268. Gertz SD, Gimple LW, Ragosta M, et al. Response of femoral arteries of cholesterol- fed rabbits to balloon angioplasty with or without laser: emphasis on the distribution of foam cells. Exp Mol Pathol 1993; 59: 225-243.
269. Kwon HM, Sangiorgi G, Ritman EL, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-1556.
270. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice [see comments]. Circulation 1999; 99: 1726-1732.
271. O’Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-682.
272. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
273. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
274. Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270.
275. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-3343.
276. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996; 5: 35-44.
277. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-917.
278. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
279. Lazarous DF, Shou M, Scheinowitz M, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996; 94: 1074-1082.
280. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest 1996; 75: 313-323.